Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?The Motley Fool • 04/28/20
Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 02/28/20
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Jazz Pharmaceuticals (JAZZ) Q4 Earnings and Revenues Top EstimatesZacks Investment Research • 02/25/20
Highly Rated Jazz Pharmaceuticals Sees A Hike In Its Composite RatingInvestors Business Daily • 02/11/20
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)Zacks Investment Research • 01/28/20